MX2024005429A - Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso. - Google Patents
Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso.Info
- Publication number
- MX2024005429A MX2024005429A MX2024005429A MX2024005429A MX2024005429A MX 2024005429 A MX2024005429 A MX 2024005429A MX 2024005429 A MX2024005429 A MX 2024005429A MX 2024005429 A MX2024005429 A MX 2024005429A MX 2024005429 A MX2024005429 A MX 2024005429A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- pi3k
- same
- alpha inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| CN2021128533 | 2021-11-03 | ||
| PCT/US2022/079221 WO2023081757A1 (en) | 2021-11-03 | 2022-11-03 | Pi3k-alpha inhibitors and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005429A true MX2024005429A (es) | 2024-05-21 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005429A MX2024005429A (es) | 2021-11-03 | 2022-11-03 | Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260125374A1 (enExample) |
| EP (1) | EP4426314A4 (enExample) |
| JP (1) | JP2024540303A (enExample) |
| KR (1) | KR20240112283A (enExample) |
| CN (1) | CN118401245A (enExample) |
| AU (1) | AU2022381187A1 (enExample) |
| CA (1) | CA3236861A1 (enExample) |
| CL (1) | CL2024001364A1 (enExample) |
| IL (1) | IL312466A (enExample) |
| MX (1) | MX2024005429A (enExample) |
| PE (1) | PE20250676A1 (enExample) |
| TW (1) | TW202334136A (enExample) |
| WO (1) | WO2023081757A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| JP6472803B2 (ja) * | 2013-09-05 | 2019-02-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾロピリジン化合物、その組成物及び使用方法 |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3931188B1 (en) * | 2019-02-26 | 2023-08-30 | Boehringer Ingelheim International GmbH | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| AU2021263914B2 (en) * | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 US US18/706,511 patent/US20260125374A1/en active Pending
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024001364A1 (es) | 2024-10-25 |
| KR20240112283A (ko) | 2024-07-18 |
| EP4426314A1 (en) | 2024-09-11 |
| IL312466A (en) | 2024-06-01 |
| CN118401245A (zh) | 2024-07-26 |
| JP2024540303A (ja) | 2024-10-31 |
| EP4426314A4 (en) | 2025-10-01 |
| US20260125374A1 (en) | 2026-05-07 |
| PE20250676A1 (es) | 2025-03-04 |
| CA3236861A1 (en) | 2023-05-11 |
| AU2022381187A1 (en) | 2024-05-16 |
| TW202334136A (zh) | 2023-09-01 |
| WO2023081757A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008103A (es) | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| NZ736709A (en) | Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase | |
| MX2017007884A (es) | Derivados de tiadiazol amida como inhibidores de la nadph oxidasa. | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2016016528A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| PH12021550857A1 (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| MX2021015656A (es) | Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX2016002764A (es) | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos. | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| PH12019502462A1 (en) | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| IL290625A (en) | Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use | |
| MX2023010566A (es) | Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso. | |
| MX2025001201A (es) | Sales y cristales novedosos |